See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot4,012▼ 0.30%WTI103.27▲ 3.82%
← 688428 page
XStocksXray
Market X-Ray report · 23 October 2026

InnoCare Pharma Ltd. A (688428)

Shanghai Stock Exchange · China · prices in CNY · close of 23 Oct 2026

Key indicators

Last closeCNY 26.60
52-week range19.36 – 35.00
Return, 1 month / 3 months−20.4% / −6.2%
Return, 1 year / 3 years+20.6% / +189.4%
TrendAbove 200-day, below 50-day
RSI (14)45
Volatility (1 year)53.8%
Worst drawdown (1 year)-35.0%
Average daily value traded361.60M CNY
Dividend yield–

Market X-Ray price-based

71/ 100 · High confidence · ahead of 88% of stocks on this exchange
Trend90
Momentum65
Stability (higher is calmer)54
Liquidity76
Income–

Five-year price chart navy: price · brown: 200-day average

5.7313.0720.4127.7435.082022-092023-092024-102025-102026-10

About the company

InnoCare Pharma is a biopharmaceutical company based in Beijing that discovers, develops and commercialises medicines for cancer and autoimmune diseases. Its main marketed product is a small-molecule drug for certain blood cancers, and its pipeline includes treatments being studied for lymphoma, autoimmune conditions and other diseases. The company serves patients and physicians through hospitals and healthcare providers in China, and it also conducts clinical development work aimed at broader markets.

The shares are listed on the Shanghai Stock Exchange in China under the code 688428, and the price on this page is in Chinese yuan (CNY). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

InnoCare Pharma Ltd. A (688428) trades on the Shanghai Stock Exchange in China. It last closed at CNY 26.60 on 23 October 2026.

Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 276 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 20.6% and over the last three months it fell 6.2%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
InnoCare Pharma Ltd. A (688428)

The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange

Lens and metricValueScoreReading
Trend90 · StrongTrading above its long-term averages and near its highs.
Above 200-day average2.5%
From 52-week high-20.4%
Momentum65 · FairTypical recent returns for this exchange.
3-month return-6.2%
6-month return-6.3%
12-month return, skipping the last month51.5%
Stability (higher is calmer)54 · FairTypical risk for this exchange.
Volatility, 1 year (lower is calmer)53.8%
Worst drawdown, 1 year (smaller is calmer)-35.0%
Liquidity76 · StrongTrades actively.
Average daily value traded361.60M CNY
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Trend: Trading above its long-term averages and near its highs.
  • Liquidity: Trades actively.

Weak spots

No lens is weak against its exchange.

Returns

1 week+2.3%
1 month−20.4%
3 months−6.2%
6 months−6.3%
1 year+20.6%
3 years+189.4%
5 years–

Signals

50-day / 200-day average28.99 / 25.96
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.74

Technical summary

DailyBearish3 bullish · 4 neutral · 9 bearish
WeeklyBullish7 bullish · 1 neutral · 4 bearish
MonthlyStrongly bullish7 bullish · 1 neutral · 0 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 24 Oct 2026